Angiotensin II - Blood
Research News and Information

Sunday, November 22, 2009

Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats.

30 Oct 2009 BACKGROUND: Perioperative beta-blockade and anemia are independent predictors of increased stroke and mortality by undefined mechanisms. This study investigated the effect of beta-blockade on cerebral tissue oxygen delivery in an experimental model ... Read more...

Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women.

23 Sep 2009 Central arterial compliance plays an important role in the functional abilities of the vasculature. Two active tripeptides, valine-proline-proline and isoleucine-proline-proline, were isolated from sour milk and were referred to as lactotripeptides ... Read more...

Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat.

12 Sep 2009 Ang-(1-7) (angiotensin-1-7), a peptide product of the recently described ACE (angiotensin-converting enzyme) homologue ACE2, opposes the harmful actions of AngII (angiotensin II) in cardiovascular tissues, but its role in liver disease is unknown. ... Read more...

Latest indexed articles for 'Angiotensin II - Blood'

These are the very latest articles for this heading:

• Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats. 30 Oct 2009
• Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. 23 Sep 2009
• Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. 12 Sep 2009
• Identification of splenic reservoir monocytes and their deployment to inflammatory sites. 29 Jul 2009
• Immunology. Dispensable but not irrelevant. 29 Jul 2009
• Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. 11 Jul 2009
• Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. 14 Jun 2009
• The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction. 30 May 2009
• Endothelial damage due to impaired nitric oxide bioavailability triggers cerebral aneurysm formation in female rats. 30 May 2009
• Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. 26 May 2009
• Hypothalamic paraventricular nucleus mediates sodium-induced changes in cardiovascular and renal function in conscious sheep. 11 May 2009
• Control by circulating factors of mitochondrial function and transcription cascade in heart failure: a role for endothelin-1 and angiotensin II. 6 May 2009
• Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. 6 May 2009
• Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension. 29 Apr 2009
• Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. 29 Apr 2009
• Effects of U50,488H on hypoxia pulmonary hypertension and its underlying mechanism. 3 Apr 2009
• Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. 30 Mar 2009
• Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. 25 Mar 2009
• A genetic variant of hypoxia-inducible factor-1alpha is associated with adverse outcomes in acute kidney injury. 9 Mar 2009
• Strain-dependent differences of restraint stress-induced hypertension in WKY and SHR. 3 Mar 2009

See a longer list of these articles.

Technical information about 'Angiotensin II'

Definition: An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.

Chemical name: Angiotensin II

Registry Number: 11128-99-7

Descriptor UI: D000804

Alternative terms: Angiotensin II; Angiotensin-(1-8) Octapeptide; ANG-(1-8)Octapeptide; Angiotensin II, Val(5)-; Valyl(5)-Angiotensin II; Angiotensin II, Valine(5)-; Angiotensin II, Ile(5)-; Isoleucyl(5)-Angiotensin II; Isoleucine(5)-Angiotensin; 5-L-Isoleucine Angiotensin II; 5 L Isoleucine Angiotensin II; Angiotensin II, 5-L-Isoleucine; II, 5-L-Isoleucine Angiotensin; Angiotensin II, Isoleucine(5)-;

Related Mesh Headings: Renin-Angiotensin System;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Vasoconstrictor Agents;

Tree Number: D06.472.699.094.078; D12.644.400.070.078; D12.644.456.073.041; D12.644.548.058.078; D12.776.641.650.070.078; D23.469.050.050.050;

History Note: 1974(1963); for ANGIOTENSIN II, ILE(5)- use ANGIOTENSIN II (NM) 1974-1999